296 related articles for article (PubMed ID: 36660669)
1. N6-methyladenosine methylation-related genes
Wang Y; Li T; Liu H; Liang Y; Wang G; Fu G; Takatsuki M; Qu H; Jing F; Li J; Jiang M
Ann Transl Med; 2022 Dec; 10(24):1398. PubMed ID: 36660669
[TBL] [Abstract][Full Text] [Related]
2. Effect of N6-methyladenosine methylation-related gene signature for predicting the prognosis of hepatocellular carcinoma patients.
Zheng X; Zhang Y; Wang Y; He Z; Zhang Q; Ren D; Yan X; Yuan X
Front Surg; 2023; 10():1052100. PubMed ID: 36936652
[TBL] [Abstract][Full Text] [Related]
3. Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma.
Liu GM; Zeng HD; Zhang CY; Xu JW
Dig Dis Sci; 2021 Apr; 66(4):1110-1126. PubMed ID: 32333311
[TBL] [Abstract][Full Text] [Related]
4. Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets.
Zhou Y; Yin Z; Hou B; Yu M; Chen R; Jin H; Jian Z
Cancer Manag Res; 2019; 11():3921-3931. PubMed ID: 31118805
[No Abstract] [Full Text] [Related]
5. N6-methyladenosine associated prognostic model in hepatocellular carcinoma.
Huang H; Bai Y; Lu X; Xu Y; Zhao H; Sang X
Ann Transl Med; 2020 May; 8(10):633. PubMed ID: 32566570
[TBL] [Abstract][Full Text] [Related]
6. Systematic analysis of the expression profile and prognostic significance of m6A regulators and PD-L1 in hepatocellular carcinoma.
Kong F; Wang K; Wang L
Discov Oncol; 2022 Nov; 13(1):131. PubMed ID: 36434140
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
Wu X; Zhang X; Tao L; Dai X; Chen P
Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
[TBL] [Abstract][Full Text] [Related]
8. The Cancer Genome Atlas (TCGA) based m
Liu J; Sun G; Pan S; Qin M; Ouyang R; Li Z; Huang J
Bioengineered; 2020 Dec; 11(1):759-768. PubMed ID: 32631107
[TBL] [Abstract][Full Text] [Related]
9. Identification and Validation of the N6-Methyladenosine RNA Methylation Regulator YTHDF1 as a Novel Prognostic Marker and Potential Target for Hepatocellular Carcinoma.
Bian S; Ni W; Zhu M; Song Q; Zhang J; Ni R; Zheng W
Front Mol Biosci; 2020; 7():604766. PubMed ID: 33363211
[No Abstract] [Full Text] [Related]
10. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.
Qi LW; Jia JH; Jiang CH; Hu JM
Front Genet; 2020; 11():614566. PubMed ID: 33519919
[TBL] [Abstract][Full Text] [Related]
11. Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma.
Zhang Y; Li L; Ye Z; Zhang L; Yao N; Gai L
Ann Transl Med; 2021 Oct; 9(20):1554. PubMed ID: 34790760
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of the N6-methyladenosine RNA methylation regulator ZC3H13 as a novel prognostic marker and potential target for hepatocellular carcinoma.
Wu S; He G; Liu S; Cao Y; Geng C; Pan H
Int J Med Sci; 2022; 19(4):618-630. PubMed ID: 35582419
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of m6A reader YTHDF2 prognosis, immune infiltration, and related regulatory networks in hepatocellular carcinoma.
Wang H; Cai H; Li L
Heliyon; 2024 Jan; 10(1):e23204. PubMed ID: 38163150
[TBL] [Abstract][Full Text] [Related]
14. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
15. Multiple m
Qu N; Qin S; Zhang X; Bo X; Liu Z; Tan C; Wen G; Jiang H
BMC Cancer; 2020 Feb; 20(1):165. PubMed ID: 32111180
[TBL] [Abstract][Full Text] [Related]
16. N
Li G; Zhang Y; Du X; Li W; Zhang Y; Han T; Zheng Z
Transl Cancer Res; 2020 Jan; 9(1):323-334. PubMed ID: 35117186
[TBL] [Abstract][Full Text] [Related]
17. m6A-Related Genes Contribute to Poor Prognosis of Hepatocellular Carcinoma.
Zou Y; Jiang G; Xie Y; Li H
Comput Math Methods Med; 2022; 2022():2427987. PubMed ID: 36339682
[TBL] [Abstract][Full Text] [Related]
18. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
20. The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma.
Li D; Li K; Zhang W; Yang KW; Mu DA; Jiang GJ; Shi RS; Ke D
Front Immunol; 2022; 13():918140. PubMed ID: 35833147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
